MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-06-2023
Aridis Pharmaceuticals Revenue 2011-2026 | ARDS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Aridis Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.09 M | 1.54 M | 1 K | 1.02 M | 2.76 M | 860 K | 2.27 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.09 M | 1 K | 1.65 M |
Quarterly Revenue Aridis Pharmaceuticals
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 417 K | - | 399 K | 292 K | 1.19 M | - | 515 K | 33 K | - | - | 1 M | 1 M | -9 K | - | 1.02 M | 1.02 M | 1.02 M | - | 1.02 M | 22 K | 322 K | - | 22 K | 22 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.19 M | -9 K | 548 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
72.3 M | $ 28.46 | 3.45 % | $ 319 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Axsome Therapeutics
AXSM
|
638 M | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Pharming Group N.V.
PHAR
|
186 M | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.37 | -4.2 % | $ 350 M |  Britain |
 |
Kamada Ltd.
KMDA
|
180 M | $ 8.5 | -1.39 % | $ 260 M |  Israel |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Benitec Biopharma
BNTC
|
75 K | $ 10.98 | -4.52 % | $ 452 M | USA |
 |
Inventiva S.A.
IVA
|
9.2 M | $ 5.78 | -4.3 % | $ 138 M | France |
 |
Compugen Ltd.
CGEN
|
6 M | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Tiziana Life Sciences PLC
TLSA
|
-82 K | $ 1.21 | -3.97 % | $ 71.5 M | Britain |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
Foghorn Therapeutics
FHTX
|
30.9 M | $ 5.0 | 2.25 % | $ 315 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
AbCellera Biologics
ABCL
|
75.1 M | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
3.22 B | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Curis
CRIS
|
10.9 M | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Coherus BioSciences
CHRS
|
42.2 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
330 M | $ 7.7 | -5.87 % | $ 1.29 B | Britain |
 |
Cellectis S.A.
CLLS
|
72.9 M | $ 3.34 | -4.02 % | $ 116 M | France |
 |
Arbutus Biopharma Corporation
ABUS
|
18.1 M | $ 4.24 | -2.97 % | $ 704 M | Canada |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cardiff Oncology
CRDF
|
593 K | $ 1.8 | -1.1 % | $ 120 M | USA |
 |
Cabaletta Bio
CABA
|
0.006 | $ 2.94 | -3.29 % | $ 3.43 M | USA |
 |
Iterum Therapeutics
ITRM
|
37 K | $ 0.16 | -5.45 % | $ 3.15 M |  Irlanda |
 |
Brickell Biotech
BBI
|
8.01 M | - | -5.38 % | $ 6.06 M | USA |